Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant vs non-concomitant administration of ZOSTAVAX with PNEUMOVAX 23 in adults ≥60 years
2007-000344-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2007
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zoster vaccine, live in herpes zoster (HZ) and pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Varicella-zoster virus antibody response and Safety and tolerability. Started Apr 2007; status: completed.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)pneumococcal disease
Beyond the preview
Go deeper on 2007-000344-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000344-26.